Catching up with Roche, Merck racks up positive data in frontline triple negative breast cancer
Merck’s Keytruda may not have qualified as a second- or third-line treatment of triple negative breast cancer, but the PD-1 inhibitor is showing promise for the first-line setting in a Phase III trial.
Investigators for the KEYNOTE-355 study report that Keytruda plus chemotherapy significantly improved progression-free survival for patients with metastatic TNBC whose tumors express PD-L1 compared to chemo alone, hitting a co-primary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.